Micro infusion pump **ipreelo**°

Implantable, Programmable and Refillable

Application Examples from peer reviewed publications



All things mouse

Pg.27-28

Cardiovascular

Pg.13, 16, 18 & 25

GLP & Toxicology

Pq.15

Infectious Disease Pq.25 Metabolism

Pq.5-8 & 28

Neuroscience Pg.9-11, 14, 19-24

Oncology

Pg.14, 17-19, 26 & 27




Implantable, Programmable and Refillable

iPRECIO Micro Infusion Pumps

<Off-the-shelf> development tool for use in drug discovery

- 1. Reduced drug requirements
- 2. Large selection of compatible solvents used in drug discovery
- 3. Easy to modulate and time exposure profiles with non-optimized compound
- 4. Easy to use/program
- 5. Available since 2007



- Solubility issues and need a higher flow rate?
- Need more control for dosage due to narrow therapeutic index?
- Want to program a drug holiday or maximize efficacy/reduce toxicity with a timed dose during the mornings?
- Want to refill with a different test article/drug (sequential administration)?





SMP-310R

The ability to program the device to start, stop and deliver different doses at different time points or just deliver one continuous dose makes iPRECIO ideally suited to the drug discovery and basic research process. All programmed in an easy to use PC based application software.

iPRECIO Micro Infusion Pumps for Drug Delivery

Exposure-enabling technology for advancing early preclinical studies and basic research

- Enables simple and complex dosing regimens at the click of the mouse/keyboard (ubiquitous PC) – several clicks
- Automation which minimizes animal handling
- Reduces stress and behavior anomalies
- Parenteral route which is practical and extremely important

Basic requirements

- Surgical skills/training (important for successful use of iPRECIO Micro Infusion Pumps)
- Basic computer skills/literacy

Resources available from Primetech

- Surgical training videos and step by step Surgical Technical Notes
- User Manual, workflows and step by step programming guide
- Compatible vehicle/solvents and easy to use compatibility test kit

What researchers are saying:

Ease of programming: "I was pleasantly surprised with how easy it was to program, fill, and implant the pumps."

Programmable & implantable pump: "This device enables implementation of infusion protocols to reliably and precisely achieve the desired exposure profiles (shapes and timing) with low degree of invasiveness."

Improved drug delivery: "The infusion pumps enhanced the delivery of the drug and allowed for us to identify a clean behavioral antidepressant effect, devoid of complications due to daily injections."

Improved drug efficacy: "This study demonstrated that an equivalent effect was possible at a much lower dose than was previously studied (25µg/serotonin hydrochloride/kg/min) in the sham and DOCA–salt rat."

Reproducible results: "I have accumulated few more very nice recordings using iPrecio. Few recording are really breath-taking by reproducibility of responses."

"Your pump is AMAZING in terms of being able to do an intra-animal dose response curve. I absolutely, positively loved this. As a pharmacologist, there is nothing better."

Lead Optimization Study: "...we use them for studies to understand the PK-PD relationship of specific molecules. In terms of the infusion protocol it would be multiple steps to achieve a specific PK concentration in a PD study."

Things went well with the last iPRECIO study. The pumps did a fantastic job as they were programmed to do. iPRECIO data were in line with predicted/calculated values. As a matter of fact, we are in the process of completing another study using the iPRECIO pumps.

Contents

- 1. Introduction > P.1
- 2. What Researchers are saying > P.3
- 3. Contents > P.4
- 4. Research Applications 1-6 > P.5
 - a Liver-derived ketone bodies are necessary for food anticipation, Nature Communication
 - Dosing Profile Profoundly Influences Nicotinic Acid's Ability to Improve Metabolic Control in Rats,
 J. of Lipid Research
 - c The abruptness of terminating nicotinic acid delivery has a profound effect on free fatty acid and insulin rebound in rats, 51st EASD Annual Meeting, Stockholm 2015
 - ${\tt d} \quad {\tt Ecto-domain\,phosphorylation\,promotes\,functional\,recovery\,from\,spinal\,cord\,injury,\,Scientific\,Reports}$
 - e Intrathecal administration using the iPRECIO® implanted pump
 - f Enhanced Resistance to Permeability Transition in Interfibrillar Cardiac Mitochondria in Dogs: Effects of Aging and Long Term Aldosterone Infusion, American Journal Of Physiology
 - g Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenegraft Model using Convection-Enhanced Delivery
- 5. GLP Studies with iPRECIO Pumps (Dual, SMP-200) > P.15
- 6. Toxicology Studies with iPRECIO Pumps (SMP-200) > P.15
- 7. Application Examples > P.16
- 8. Webinars including: Compound Delivery, PK-PD & Validation Studies in Oncology Studies on InsideScientific and related Key Publications.:- > P.17
- 9. The Ultimate Choice for Neuroscience > P.19
- 10. Additional Highlights.:- > P.22
 - Miniaturized Neural System for Chronic, Local Intracerebral Drug Delivery (MiNDS)
 - Labor induction with oxytocin in pregnant rats is not associated with oxidative stress in the fetal brain.
 - <US Patent App.> 20180161282 Methods & compositions for the treatment of seizure-related disorders.
 - < WO2020221821A1> Pulsative gnrh administration for treating cognitive disorders
 - Intermittent micafungin for prophylaxis in a rat model of chronic Candida albicans gut colonization
 - MitoTEMPO normalized ROS and prevented heart failure and arrhythmias

11. iPRECIO Micro Infusion Pumps for Cancer Research > P.26

Program what you need for overcoming:-

- a. Narrow therapeutic index
 - i. Maximizing efficacy with timed infusion
 - ii. Minimizing toxicity with timed infusions
 - iii. Flexibility to program 101 discreet infusion flow-rates. (SMP-310R, 0.0 to 10.0µl/hours)
- 12. All things mouse with iPRECIO Programmable Pumps > P.27-28
- 13. Example Pump implantation site and drug administration site > P.29
- 14. Support Materials > P.29
 - a. Technical Note / Surgical Protocol
 - b. Surgical Videos
- 15. Product Information > P.31
- 16. Compatible solvents > backpage

Research Applications 1

SC Administration

Timed release of Test Article (TA), ßOHB

Rohit Chavan, Céline Feillet, Sara S. Fonseca Costa, James E. Delorme, Takashi Okabe, Jürgen A.Ripperger & Urs Albrecht

Liver-derived ketone bodies are necessary for food anticipation.

Nature Communications 7, Article number: 10580 doi:10.1038/ncomms10580

http://www.nature.com/ncomms/2016/160203/ncomms10580/full/ncomms10580.html?WT.ec_id=NCOMMS-20160205




Figure 1 (Figure 4a in Full Article) **Rescue of food anticipation in L Per2**-/-mice by ß-hydroxybutyrate. (a) Timed release of ßOHB (green) but not NaCl (white) or Na-Pyruvate (purple) in L Per2-/- mice mimics the ßOHB levels in plasma of L Per2+/+ control animals (black). Measured after 15 days of infusion. Figure reproduced from Chavan et al. in Nature Communications as reference previously.

Figure 1 is reproduced from Liver-derived ketone bodies are necessary for food anticipation. http://www.nature.com/ncomms/2016/160203/ncomms10580/full/ncomms10580.html?WT.ec_id=NCOMMS-20160209 under Creative Common Attribution 4.0 International (CC BY 4.0) http://creativecommons.org/licenses/by/4.0/.

No changes were made for reproduction from Figure 4a of Chavan et al.

Purpose of the study:

Researchers were interested to know where Food Anticipation (FA) signals originate and what role components of the circadian clock might play. To test the potential of ßOHB as FA signal, iPRECIO SMP-300 programmable minimpumps were used to release ßOHB s.c. 6 hours prior to meal time under Restricted Feeding (RF) at ZT22 to reach a concentration normally observed in WT mice under RF preceeding feeding time.

iPRECIO SMP-300 pumps were used to test the potential of ßOHB as a FA signal.

Short methods or use of the pumps:

iPRECIO SMP-300 pumps were programmed to infuse saline vehicle at 2 ul/h, or D-\(\text{SOHB} \) at 2 ul/h, or Sodium pyruvate at 5 ul/h, or coconut oil at 5 ul/h prior to meal time (6 h, ZT22-ZT4) under Restricted Feeding (RF)

Results/significance:

Liver-derived ketone bodies are necessary for food anticipation.

Timed Release of ßOHB partially rescues FA.

Research Need:

Timed Release of ßOHB in free moving animal with minimum or no handling to reduce stress and any confounding effects.

Additional information on mini-pump implant

Male and female L Per2+/+ and L Per2-/- mice (3-5 months old)Telemetry transmitter (G2 Emitter) was i.p. implanted in each mouse under gaseous anaesthesia. At least 10 days after the transmitter implantation an iPRECIO programmable micro infusion pump (SMP/UCD 300; Primetech Corp., Japan) was implanted in subgluteal space(s.c. administration) on the back of each L Per2-/- mouse. Subcutaneous administration.

Related Circadian rhythm Research using iPRECIO SMP-200 in mice

In vivo imaging of clock gene expression in multiple tissues of freely moving mice Nature Communications 7, Article number: 11705 doi:10.1038/ncomms11705

https://www.nature.com/articles/ncomms11705

Research Applications 2

SC Administration

Can different dosing (12 hour rectangular exposure profile) and terminating profile (a slow-step down) of Nicotinic Acid (NiAc) prevent/delay tolerance development and attenuate the FFA rebound development respectively.

Tobias Kroon (2016) PhD Thesis,

<Optimizing Nicotinic Acid Delivery for Durable Anti-lipolysis and Improved Metabolic Control>,

http://pub.epsilon.slu.se/13324/

http://pub.epsilon.slu.se/13324/1/kroon_t_160429.pdf

Thesis and publications cover Drug Discovery implications

- 1. Importance of time-series disease model
- 2. Continuous vs. intermittent drug exposures /Programmable, implantable mini-pump
- 3. Time exposure to physiology/Shape of exposure
- 4. Meta-analysis/Rank candidates/Predict designs

Tobias Kroon, Ann Kjellstedt, Pia Thalén, Johan Gabrielsson, Nicholas D. Oakes

Dosing Profile Profoundly Influences Nicotinic Acid's Ability to Improve Metabolic Control in Rats

The Journal of Lipid Research, doi: 10.1194/jlr.M058149, July 13, 2015

http://www.jlr.org/content/early/2015/07/13/jlr.M058149.abstract

Kroon T, Baccega T2, Olsén A, Gabrielsson J, Oakes ND

Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats [S].

J Lipid Res. 2017 Jan; 58 (1): 31-41 Doi: 10.1194 / jlr.M 068395. Epub 2016 Nov 15.

https://www.ncbi.nlm.nih.gov/pubmed/27875257





Fig. 2 (Figure 1 in Kroon et al.)

A: NiAc and saline infusion profiles across studies I-III.

Black (NiAc) and open (saline) bars represent time periods of constant rate infusions during days 1–5. B: Terminal protocol for studies I (NiAc-induced FFA lowering) and III (NiAc-induced changes in adipose tissue gene expression).

C: Terminal protocol for study II (hyperinsulinemic-isoglycemicla clamps).






Fig. 3. (Figure 5 in Kroon et al.) Plasma insulin (A, B) and glucose (C. D) concentration in lean (left) and obese (right) following infusion of saline (lean n = 5, obese n = 12) or NiAc (0.17µmol·min -1·kg -1) given acutely (NiAc naïve, n = 7/group) or following 5 days continuous (Cont. NiAc, lean n = 4, obese n = 8) or intermittent (Inter. NiAc, lean n = 4, obese n = 9) or 11 days intermittent (Inter. NiAc Day 11, obese n = 4) dosing. The black horizontal bar represents the period of acute NiAc/saline infusion. Data presented as mean \pm SE.

Figures 2 and 3 licensed material. © <2015> The American Society for Biochemistry and Molecular Biology. Warranties: None Publisher makes no representations or warranties with respect to the licensed material and adopt on its own behalf the limitations and disclaimers established by CCC on its behalf in its Billing and Payment terms and conditions for this licensing transaction.

Purpose of the study:

Dosing Profile Profoundly Influences Nicotinic Acid's Ability to Improve Metabolic Control in Rats

Researchers wanted to compare the ability of continuous versus intermittent NiAc administration to suppress FFA levels in metabolic healthy and insulin-resistant rats.

The abruptness of terminating nicotinic acid delivery has a profound effect on free fatty acid and insulin rebound in rats

The aim of this study was to determine whether a slow step-down NiAc infusion protocol (Step-Down group) vs. simply turning infusion off (On/Off group) could attenuate the FFA rebound development.

iPRECIO SMP-200 pumps were programmed to deliver the required exposure profiles of Nicotinic Acid to study impact on tolerance development (see figure 2A) and attenuate the FFA rebound development respectively (not shown)

Results/significance:

An Intermittent NicAc dosing strategy succeeded in retaining FFA lowering and improving insulin sensitivity in obese Zucker rats. Gradual step-down reduction of NiAc infusion actually degraded the anti-lipolytic effectiveness of NiAc compared to abrupt withdrawal.

Research Need:

Ability to quickly and easily adjust dosing profiles based on PK and PD effects and deliver doses without stressors which could change metabolic activity of animals.

Intrathecal Administration

Research Applications 3

Continuous infusion of PKA and ATP at 1µl/hour for 14 days where solution in pump was changed every 2 days due to stability of PKA and ATP.

Kenji Suehiro, Yuka Nakamura, Shuai Xu, Youichi Uda, Takafumi Matsumura, Yoshiaki Yamaguchi, Hitoshi Okamura, Toshihide Yamashita & Yoshinori Takei

Ecto-domain phosphorylation promotes functional recovery from spinal cord injury

Scientific Reports 4, Article number: 4972 (2014) doi:10.1038/srep04972

http://www.nature.com/articles/srep04972




Figure 4 is reproduced from Ecto-domain phosphorylation promotes functional recovery from spinal cord injury http://www.nature.com/articles/srep04972 under Creative Common Attribution 4.0 International (CC BY 4.0) http://creativecommons.org/licenses/by/4.0/.
No changes were made for reproduction from Fig. 1 of Suehiro et al.

Figure 4 (Figure 1 from Suehiro et al)

| Treatment with PKA plus ATP diminishes damage from traumatic SCI. (a) The depth of injury and location of sections used in (c) are illustrated schematically. The dorsal corticospinal tract (dCST) and the dorsolateral corticospinal tract (dlCST) were severed. (b) The BBB scores of vehicle-treated, PKAtreated, ATP-treated and PKA1ATPtreated SCI rats were assessed at the indicated days after SCI. The points on the graph indicate the average BBB score from six independent rats, and the error bars indicate the standard deviation (S.D.) (*p, 0.05, **p, 0.01, ***p, 0.001 vs.vehicle-treated rats. Student's t-test), (c) The BDAlabelled dCST was visualised. Images are taken from transverse sections at either 5 mm caudal or rostral to the lesion, as shown in (a). The bar indicates 25 mm. (d) The number of BDA-positive axons at T8 or T10 was normalised to the number of BDA positive axons at C1 (intact region of the spinal cord). The average and the S.D. from three independent animals are shown. No significant differences between the vehicle-treated rats and the PKA/ATP-treated rats were observed (*p., 0.05, **p., 0.01,

Purpose of the study:

Investigate if inhibition of Nogo-66 receptor (NgR) via ecto-domain phosphorylation by protein kinase A (PKA), which blocks activation of the receptor can promote recovery following spinal cord injury.

iPRECIO SMP-200 pumps were used to infuse PKA plus ATP for 14 days at 1µl/hour. Solution in reservoir was changed every 2 days.

Results/significance:

Authors found that infusion of PKA plus ATP into the damaged spinal cord can promote recovery of locomotor function.

Research Need:

Ability to replace unstable test articles or drugs easily and rapidly without additional surgeries and stress.

Related publication examples: Refilling to Improve Test Article Stability

Hemoglobin induced lung vascular oxidation, inflammation, and remodeling contributes to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeat dose haptoglobin administration

Free Radical Biology and Medicine D Irwin et

al.doi:10.1016/j.freeradbiomed.2015.01.012

http://www.sciencedirect.com/science/article/pii/S0891584915000192

Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism.

Am J Physiol Lung Cell Mol Physiol. 2012 Aug;303(4):L312-26. Epub 2012 Jun 22.

http://www.ncbi.nlm.nih.gov/pubmed/22728465

Research Applications 4

Intrathecal Administration

Excerpt from Mitchell et al. Full reference in box.

Regulatory request to perform an epidural and/or intrathecal animal study to assess degradents associated with a pharmaceutical product that was given epidurally in humans.

Mitchell D., Read, K., Chapman M. and Patten D.

Intrathecal administration using the iPRECIO® implanted pump

Development in Life Sciences, Vol 14, No. 4

http://cdn2.hubspot.net/hubfs/212573/docs/Envigo/Envigo_Pharma_Dils_14.4.4.pdf?t=1460116975327

Purpose of the study:

The customer requested a rat study involving intrathecal infusion for 72-hours of two different degradent mixtures and appropriate controls with acute and delayed endpoints and investigations of local and systemic toxicity. Clinical relevant concentrations of degradents to attain comparable exposure with humans would be necessary.

Developments in LifeSciences Vol. 14 No. 4

Intrathecal administration using the iPRECIO[®] implanted pump

David Mitchell BSc (Hons) DABT, Senior Toxicologist, Toxicology Operations, Envigo, UK.
Kate Read MA VeMM MRCVS, Veterinary Clinician, Veterinary Services, Envigo, UK.
Melissa Chapman BSc (Hons), Senior Study Director, Toxicology Operations, Envigo, UK.
Duncan Patten FIAT RAnTech, Associate Director, Laboratory Animal Technologies, Envigo, UK.

The background to this project was a regulatory request to perform an epidural and/or intrathecal animal study to assess degradents associated with a pharmaceutical product that was given epidurally in humans. There was a concern that there might be inadvertent intrathecal administration of the product and degradents. The customer requested a rat study involving intrathecal infusion for 72-hours of two different degradent mixtures and appropriate controls, with acute and delayed toxicity endpoints and investinations of local and systemic toxicity. We had

could compromise welfare, in particular for clinical signs associated with increased intrathecal pressure.

The optimal solution was to use the

iPRECIO* SMP-200 programmable peristaltic pump implanted

subcutaneously and linked to an

intrathecal catheter

iPRECIO SMP-200 pumps were used to infuse 1µl/hr of artificial CSF intrathecally following surgery and during the recovery period. Animals recovered well with no adverse clinical signs in the post –operative period. During the treatment period; infusion at 30µl/hr, a small number of animals (5 out of 72) showed hindlimb paresis. Examination of aspirated dose volumes demonstrated accurate pump function.

Results/significance

This method (iPRECIO SMP-200 linked to an intrathecal catheter) is suitable for controlled continuous infusion into the intrathecal space of the rat. The surgical procedure is reproducible and considered to be less invasive than intrathecal access via the cisterna magna. The use of the programmable iPRECIO® pump allows for an ambulatory infusion model without the need to tether the animals. This permits behavioural assessment and is an improvement in animal welfare; animals are able to display normal behaviours post operatively.

Research Need:

A standard method for intrathecal infusion in industry and academia which would not be a confounding factor in the assessment of CNS endpoints (modified Irwin assessment). The infusion system must provide a suitable flow rate over at least 72 hours.

- •The pump must allow the flexibility to start infusion immediately following surgery or at a later time.
- The pump must have a reservoir that can be evacuated and refilled, percutaneously, by syringe and needle so there would be the opportunity for a period of recovery from surgery before administration of the degradant mixtures while avoiding the risk of catheter occlusion by administering saline or artificial cerebrospinal fluid.

Research Applications 5

Jugular Vein (IV) Administration

Aldosterone was continuously infused with SMP-200 programmable infusion pump that delivered aldosterone into the jugular vein. D-Aldosterone was infused into the jugular vein at a dose of 30 $\mu g \cdot kg^{-1} \cdot day^{-1}$ in a solution of 15% ethanol,

50% DMSO, and 35% water at a concentration of 10 mg aldosterone/ml.

Enhanced Resistance to Permeability Transition in Interfibrillar Cardiac Mitochondria in Dogs: Effects of Aging and Long Term Aldosterone Infusion.

Am J Physiol Heart Circ Physiol aipheart.00674.2012;

http://ajpheart.physiology.org/content/early/2012/12/10/ajpheart.00674.2012.abstract?sid=1c8187a4-b1a5-41e2-9e88-20610af15128

Purpose of the study:

Effect of aging and long-term aldosterone infusion on respiratory function and resistance to mitochondrial permeability transition (MPT) in subsarcolemmal and interfibrillar cardiac mitochondria (SSM and IFM) from healthy young (1 year) and old (8 year) female beagles.

iPRECIO SMP-200 pumps were used to infuse Aldosterone for 14 weeks at a dose of 30 µg·kg⁻¹·day⁻¹ The pump reservoir was 900 µl and was refilled percutaneously every 20–30 days through an injection port on the pump. The pump reservoir was evacuated before refilling to ensure the pump had properly discharged its contents and was then refilled using a 26-gauge needle. This procedure was done in conscious animals with no evidence of discomfort.

Results/significance

Authors demonstrated in a large animal model that resistance to MPT is greater in IFM than in SSM in young and old female dogs. When old dogs were stressed with aldosterone infusion, there was selective enlargement of SSM and greater susceptibility to MPT, with no change to IFM.

Research Need:

Long term/chronic 14 week infusions with the ability to refill and check performance of implanted pumps.

Research Applications 6

Brain Administration

Pumps were programmed to instant mode, constant mode and 5µl/hour infusion rate.

They were initially loaded with isotone saline or 0.1 mM MTX. Two days later, residual saline or MTX was extracted from the pump reservoirs and refilled with 960 μ l of 0.3 μ g/ml ¹²⁵l-UdR or ¹²⁷l-UdR. See figure 6 below for results obtained. Reproduced with permission from Thisgaard et al. (CC BY-NC-ND 4.0).

Thisgaard et al.

Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced DeliverHighly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Deliver

Theranostics 2016, Vol. 6, Issue 12 2016; 6(12): 2278-2291. doi: 10.7150/thno.15898

http://www.thno.org/v06p2278.htm




Figure 6. Kaplan-Meier plot showing that the survival benefit of neoadjuvant MTX + ¹²⁵I-UdR as stand-alone Auger-therapy (group4) or with concomitant, systemic TMZ chemotherapy (group5) was highly significant compared with the non-radioactive, but chemically identical treatment MTX + ¹²⁷I-UdR (group3, p=0.0001 and p<0.0001, respectively) or untreated controls (group1, both p<0.0001). The Auger-therapy was also significantly better than systemic TMZ-chemotherapy alone (group6, p=0.0001). Reproduced with permission from Thisgaard et al. (CC BY-NC-ND 4.0).

Purpose of the study:

The overall aim of this was to test the effect and safety profile of ¹²⁵I-UdR therapy in vitro and in vivo on immature Glioblastomas (GBMs) spheroid cultures (GSCs) and orthotopic xenografted GBM-bearing rats, respectively. A further objective was to determine if further therapeutic effect was achieved when combining ¹²⁵I-UdR therapy with the currently used first-line chemotherapeutic agent TMZ.

Pumps were initially loaded with isotone saline or 0.1 mM MTX. Two days later, residual saline or MTX was extracted from the pump reservoirs and refilled with 960 μ l of 0.3 μ g/ml ¹²⁵I-UdR or ¹²⁷I-UdR.

Results/significance

The multidrug approach including CED of MTX and the AEE-compound ¹²⁵I-UdR in combination with systematic TMZ was safe and very effective in the orthotopic xenograft GBM model, leading to 100% survival.

Research Need:


The ability to evaluate combinational therapy/multidrug approach easily and rapidly without additional surgeries and stress.

GLP Studies with iPRECIO Pumps

Laura Ringer

The use of the iPRECIO Dual Inlet Infusion Pump in Ambulatory Cardiovascular Dog Studies

DSI East Coast User Group Meeting, Philadelphia, PA, United States October 29th and 30th 2015




Duncan Patten (Huntingdon Life Sciences, UK)

Use of iPRECIO implantable micro infusion pumps in rats

4th Infusion Technology Organization Meeting, May 8th-9th 2014, Harrogate, UK.

Perron J., Frenette V., and Copeman C.

Validation and use of the iPRECIO® Micro Infusion Pump on GLP studies Society of Toxicology Annual Meeting, San Francisco, United States, March 11th to 14th 2012.



Toxicology Studies with iPRECIO Pumps

Masaru Tsuboi, Yoshihide Ueda, Yasufumi Ota, Hiroshi Takehara, Takuya Aoshima, Fukutaro Mizuhashi


Physiological conditions in iPRECIO® -implanted rats

Fundamental Toxicological Sciences Vol.3 (2016) No.1 p.1-8

https://www.jstage.jst.go.jp/article/fts/3/1/3_1/_article

Application Examples

5-HT dose response with control period : 5-25 greater sensitivity



Drug Delivery: Enabling Technology for Drug Discovery and Development.


iPRECIO® Micro Infusion Pump:

Programmable, Refillable, and Implantable

Tsung Tan, Stephanie W. Watts, and Robert Patrick Davis Front Pharmacol. 2011; 2: 44. Published online 2011 July 29. doi: 10.3389/fphar. 2011.00044

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149148/

Dose response: Dobutamine, verapamil & saline 3 test articles per animal (pump)




Drug Delivery: Enabling Technology for Drug Discovery and Development. iPRECIO® Micro Infusion Pump:

Programmable, Refillable, and Implantable

Tsung Tan, Stephanie W. Watts, and Robert Patrick Davis Front Pharmacol. 2011; 2: 44. Published online 2011 July 29. doi: 10.3389/fphar. 2011.00044

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149148/

100nl bicuculline methiodide (BMI) bolus injections



Zaretsky D.V., Zaretskaia M.V., Durant P.J., Rusyniak D.E.

The use of microinfusion pump to perform intrahypothalamic injections in conscious rats.

Neuroscience 2012, New Orleans, USA., October 13th - 17 2012

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2964&sKey=87d8b951-316f-466a-9eb7-4b154d0bbd2c&cKey=b4b8338f-9bd2-44e2-bcf4-6e05a36cbbcb&mKey=%7b70007181-01C9-4DE9-A0A2-EEBFA14CD9F1%7d

Comparison of arterial pressure and plasma ANG II responses to three methods of subcutaneous ANG II administration

Comparison of arterial pressure and plasma AnglI responses to three methods of subcutaneous AnglI administration Kuroki M.T. . , Gregory D. Fink , John W. Osborn

American Journal of Physiology - Heart and Circulatory PhysiologyJul 2014, DOI: 10.1152/ajpheart.00922.2013 http://ajpheart.physiology.org/content/early/2014/06/30/ajpheart.00922.2013

Webinar


Webinar: Compound Delivery, PK-PD & Validation Studies in Oncology Studies

Christian Schnell, Associate Director Oncology NIBR Novartis in Basel

https://insidescientific.com/webinar/programmable-pumps-for-compound-delivery-in-oncology-research/

Programmable pumps for compounds delivery in oncology research: implication for refinement and reduction of animal use

Validation study in freely moving grouped housed nude **mice and rats** via an programmable iPRECIO pump **using all tested doses and compound** (i.v. via jugular vein)



During this on-demand webinar, Christian Schnell describes the validation studies performed in his pharmacology unit in rats and mice. Accurate PK-PD assessment and corresponding antitumor activity were assessed among several drug discovery programs.

Presentation Highlights:

- Traditional methods used for developing PK/PD models (4:00)
- PK/PD models and the limitations of traditional dosing methods (6:33)
- Methods and benefits of implantable microinfusion pumps in both rats and mice (12:36)
- Validation studies using implantable pumps (17:41)
- Experimental application of implantable pumps (24:36)
- The use of implantable pumps to assess TI (28:18)
- Potential future applications and considerations (36:05)

Related Reference.


Weiss, Andreas, et al. "Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C." Cancer Discovery 12.6 (2022): 1500-1517.

- iPRECIO SMP-310R Programmable pumps were used to better understand the relationship between PK, target occupancy, and efficacy.
- Continuous infusion demonstrated that Daily AUC rather than Cmax or Time-over-threshold as the driver of efficacy of TDQ443.

Weiss, Andreas, et al. "Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRAS^{G12C}."

Cancer Discovery 12.6 (2022): 1500-1517. https://doi.org/10.1158/2159-8290.CD-22-0158 [Open Access]

"To assess the effect of continuous dosing on tumor growth, LU99 tumor-bearing nude mice were implanted subcutaneously with a programmable microinfusion pump (iPRECIO,



Primetech Corporation) SMP310R. previously described (56). For this purpose, the catheter connected to the microinfusion pump was inserted into the left external jugular vein via midcervical incision, and the body of the microinfusion pump was implanted subcutaneously on the flank of the mice opposite to the xenograft tumor. For infusion. JDQ443 was dissolved in 30% PEG and 10% Kolliphor at a concentration of 3 and 10 mg/mL. The infusion rate of 4 µL/h programmed with **iPRECIO** Management Software v1.0.4.0. Pumps were refilled with vehicle or JDQ443 daily. At days 2 to 3, 9 to 10, and 12 to 13, the drug released was quantified in blood samples collected at the tail vein by LC-MS/MS. "excerpt without modification according to Attribution-Non Commercial-No

International BY-NC-ND4.0) 4.0

Webinars with iPRECIO Pump use. "(1) The best solution is to get rid of stress because training is not really a solution. (2) An implantable pump is the only way to deliver the compound without interfering at the moment of delivery.".

WE 1 Schnell: Gold Standard Physiological Measurements and Novel Drug Delivery Methods: Quality Data in Mice to Marmosets. Christian Schnell, Associate Director Oncology NIBR Novartis in Basel

https://insidescientific.com/webinar/gold-standard-physiological-measurements-and-novel-drug-delivery-methods-iprecio-pt1/

WE 2 Doyle: Gold Standard Physiological Measurements and Novel Drug Delivery Methods: Synthetic, Structural, and Mechanistic Investigations of Vitamin B12 Conjugates of the Anorectic Peptide PYY3-36 Dr Robert Doyle, The Laura J. and L. Douglas Meredith Professor of Biochemistry and Biotechnology, Syracuse University, Syracuse. https://insidescientific.com/webinar/gold-standard-physiological-measurements-and-novel-drug-delivery-methods-iprecio-pt2/

Henry, Kelly E., et al. "Vitamin B12 conjugation of peptide-YY3-36 decreases food intake compared to native peptide-YY3-36 upon subcutaneous administration in male rats." Endocrinology 156.5 (2015): 1739-1749. https://academic.oup.com/endo/article/156/5/1739/2422996?login=true

The Ultimate Choice for Neuroscience

iPRECIO Micro Infusion Pumps for Drug Delivery Implantable Programmable Refillable

- ·The only way to deliver compound without interfering at the moment of delivery
- · Paired data sets: Program a recovery/baseline period prior to drug delivery for control period for comparison.
 - > Recovery period after surgery (pump stop or saline infusion)
 - > Baseline period (pump stop or saline infusion)
 - > Drug delivery /Treatment period (start pump or exchange from saline to drug)
 - Continuous
 - Intermittent
 - Dose escalation / de-escalation
 - Circadian
 - > Reversibility (pump stop or exchange to saline)
- · Infuse directly to brain
- · Infuse directly to intrathecal space
- ·SC, IP and IV administration

Example Drug Delivery Regimen (Figure 1 reproduced from Thisgaard et al. (CC BY-NC-ND 4.0) Schedule what you require: program and/or exchange infusate as per study requirements




Figure 1 reproduced from Thisgaard et al. (CC BY-NC-ND 4.0)

Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery Thisgaard et al. Theranostics 2016, Vol. 6, Issue 12 2016; 6(12): 2278-2291. doi: 10.7150/thno.15898

http://www.thno.org/v06p2278.pdf Attribution-Non Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0)

Selected CNS Publications

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism

BRIEF RESEARCH REPORT ARTICLE Front, Neurol., 05 December 2019

https://www.frontiersin.org/articles/10.3389/fneur.2019.01258/full

Key words: intracerebral brain infusion, levodopa-induced dyskinesia, memantine, N-methyl-D-aspartate receptor, Parkinson's disease





Figure 1A reproduced without modification from doi.: 10.3389/fneur.2019.01258. Attribution 4.0 International (CC BY 4.0) https://crealivecommons.org/licenses/by/4.0/

Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?

Neurobiology of Disease, Vol. 103, 2017, 24-31

http://dx.doi.org/10.1016/j.nbd.2017.03.013

Pump setting delivery in 6-OHDA rats:



Supplementary Image 1.

Dopamine delivery from the pump trough the rat brain cannula begin each day from zeitgeber time -10h (i.e. 9pm) to zeitgeber time 6 h (i.e. 1pm), over 16h during 30 days. Image 1 & text reproduced without modification from C. Laloux et al. (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/

Rhythmic Release of Corticosterone Induces Circadian Clock Gene Expression in the Cerebellum

Neuroendocrinology. 2019 Sep 27. doi: 10.1159/000503720

https://www.karger.com/Article/Abstract/503720

Key words: Cerebellum, Circadian, Clock gene, Corticosterone, Suprachiasmatic nucleus,iPRECIO programmable micropump

Investigate drug-evoked adaptations with different patterns of exposure.

Selected CNS Applications with iPRECIO Micro Infusion Pumps Addiction/ Drug abuse liability

- Adversive effects of drug withdrawal in rats and mice
- Withdrawal Test
 - > Test potential compounds which may have similar effects in the same animals or reduce the signs of withdrawal
 - > Abrupt cessation

Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system

Neuropsychopharmacology (2020) | Published: 20 February 2020

https://doi.org/10.1038/s41386-020-0643-x Subjects: Addiction, Reward

Discrimination Learning in Oxycodone-Treated Nonhuman Primates

Drug and Alcohol Dependence, Available online 27 November 2019, 107778

https://doi.org/10.1016/j.drugalcdep.2019.107778

Keywords: Opioid, Oxycodone, Naltrexone, Self-administration, Withdrawal, Cognition, Nonhuman primate

Convergent and Divergent Behavioral Changes Caused by Different Patterns of Morphine Exposure in Mice

International Narcotics Research Conference (INRC), Chicago, 9 - 14 of July 2017 https://www.fournay.och/iow/324/ahstracts/#5203

Mechanisms specific to methamphetamine-associated memory disruption by nonmuscle myosin II inhibition

420.01 / SS23, Neuroscience Annual Meeting 2017, Nov 11th to 15th 2017 Washington DC http://www.abstractsonline.com/pp8/#!/4376/presentation/16699

CDKL5 PROTEIN SUBSTITUTION THERAPY RESCUES NEUROLOGICAL PHENOTYPES OF A MOUSE MODEL OF CDKL5 DISORDER

Human Molecular Genetics, ddy064, https://doi.org/10.1093/hmg/ddy064 https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddy064/4892297?redirectedFrom=fulltext

Differential effects of nicotine and nicotine withdrawal on fear conditioning in male rats [Open Access]

International Journal of Neuropsychopharmacology, pyaa024,

https://doi.org/10.1093/ijnp/pyaa024

Key words: Nicotine, PTSD, Fear Conditioning, Withdrawal

Additional Highlights: MiNDS

Fortunately for us, iPRECIO® too. Playing our small part for Science.



CC BY-NC-ND*,
Credit M. Scott Brauer
Miniaturized Neural System for Chronic,
Local Intracerebral Drug Delivery
(MiNDS)

*CC BY-NC-ND: Attribution-NonCommercial-NoDerivatives 4.0 International

https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode

https://www.media.mit.edu/projects/miniaturized-neural-system-for-chronic-local-intracerebral-drug-delivery/press-kit/

Miniaturized neural system for chronic, local intracerebral drug delivery

Science Translational Medicine 24 Jan 2018: Vol. 10, Issue 425, eaan2742

DOI: 10.1126/scitranslmed.aan2742

http://stm.sciencemag.org/content/10/425/eaan2742


Focal, remote-controlled, chronic chemical modulation of brain microstructures

PNAS July 10, 2018 115 (28) 7254-7259; https://doi.org/10.1073/pnas.1804372115

Giri, Tusar, et al. "Labor induction with oxytocin in pregnant rats is not associated with oxidative stress in the fetal brain." Scientific reports 12.1 (2022): 1-12.

https://www.nature.com/articles/s41598-022-07236-x [Open Access]

Experimental schematic for labor induction with oxytocin in term pregnant rats. (A) A cartoon depicting the programming and implantation of iPRECIO pump in a pregnant rat followed by birth of healthy



pups. Reproduced without modification

under Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/

Additional Highlights: United States Patent Application 20180161282

Methods and compositions for the treatment of seizure-related disorders by Adamas Biopharmaceutical Inc. (https://www.adamaspharma.com/) includes references to iPRECIO Micro Infusion Pump use in Examples 13 to 16. In example 13, "The PK parameters (Cmax, Tmax, T1/2, AUC) of 200 mg IR lacosamide BID and 400 mg ER lacosamide QD in humans can be replicated in rats using programmable

- CNS side effects were compared when delivered as a continuous infusion in rats
 to simulate an extended release (ER) plasma profile or as a bolus to simulate
 an immediate release (IR) plasma profile.
- CNS side effects were measured as an impairment of motor coordination in rodents using the rotor-rod.

Excerpts from US Patent Publication 20180161282

Example 13: Pharmacokinetic Study of Lacosamide Administered by Continuous Subcutaneous Infusion to Rats for 7 Days

The objective of this study is to demonstrate that the PK profile from a standard regimen of 200 mg IR lacosamide BID in humans, along with a novel PK profile of 400 mg ER lacosamide QD, can be replicated in rats using programmable subcutaneous infusion pumps. Jugular vein cannulated male and female Sprague Dawley rats weighing between 240-260 grams are used for this study. Rats are implanted with programmable infusion pumps (iPRECIO SMP-200)

Example 14: - related to training for Rotor-rod Training and Test

Following the period of acclimation, rats are surgically implanted with subcutaneous programmable pumps (iPRECIO), per the manufacturer's instructions. Prior to implantation, pumps are pre-programmed and filled with sterile 0.9% saline according to the manufacturer's instructions. Implantation is done under anesthesia by using aseptic techniques.

Three days following pump implantation surgery, rats are pre-trained on the rotarod and assigned to treatment groups based on their body weights.

Infusion of lacosamide commences on day four post-pump implantation surgery. Baseline measurements are made on the rotarod on Day 4. Immediately thereafter, saline in the iPRECIO pumps is withdrawn and the pump is refilled with lacosamide solution (25 mg/mL in 0.9% saline). Pumps are refilled during the 7 day period as necessary, through the access port of the iPRECIO pump.

Excerpts from US Patent Publication 20180161282 continued.

for Simulated BID dosing

TABLE EX 13A: Study Design and Infusion Protocol

Group	Number of animals	Dose Period ²	Dose rate/rat ¹ (mg/h/rat)	Concentration in pump (mg/mL)	Pump Flow rate (µL/h)	Plasma Collection Times (hours)
1	4	0 - 2 h	0.59	20	29.5	1, 4, 8, 14, 20
		2 - 12 h	0.12	20	6	84, 144, 158
2	4	0 - 2 h	0.59	20	29.5	2, 6, 12, 18
		2 - 12 h	0.12	20	6	24, 98, 156, 168

¹ Lacosamide dose estimates are based on average animal body weight of 250 g

For further information see patent application,

https://patents.google.com/patent/US20180161282A1/en?og=20180161282


WO2020221821A1 Pulsative gnrh administration for treating cognitive disorders [Open Access]

Vincent PREVOT Andrea MESSINA Paolo GIACOBINI Valérie LEYSEN Maria MANFREDI LOZANO

https://patents.google.com/patent/WO2020221821A1/en?og=WO2020221821A1

Excerpts from patent application WO2020221821A1 (Down syndrome DS - Ts65Dn mice, Route of administration (RoA) -SC)

"Without access to the iPRECIO micro infusion pumps, our experiments would have been almost impossible. As they require an injection every 3h over a period of 2 weeks, it would have been very difficult to impossible to have performed the experiment manually."



"Adult mice were implanted with osmotic minipumps (1002, Alzet, USA) receiving continuous infusion of vehicle (sterile 0.1M PBS) or LUTRELEF® (0.25 pgr/ 3h) (Ferring Pharmaceuticals, Switzerland); or with a programmable micro infusion pump (SMP-300, iPRECIO, Japan) receiving pulsatile infusion of vehicle or LUTRELEF® (every 3 hours, a peak of 0.25 pg during 10 min), mimicking GnRH/LH pulsatility reported in WT mice (Czieselsky et al, 2016), and a basal infusion with a low dose (0.0025 pg/10 min) for the rest of the time. The pumps were placed under the skin on the back of the mouse. Both olfactory and cognitive deficiencies were confirmed before in these animals. One week after the surgery, mice were retested to evaluate their olfactory and cognitive performance. Two weeks after the surgery, repetitive tail-tip blood sampling was undertaken (as described elsewhere) to assess the LH pulsatility profile." from WO2020221821A1 Patent Application.

² Pump infusion protocol is repeated every 12 hours for a total of 7 days

Additional Highlights: Our Programmable iPRECIO minipumps used to administer humanized doses of antifungal. Journal of Antimicrobial Chemotherapy. Intermittent micafungin for prophylaxis in a rat model of chronic Candida albicans gut colonization [first study to administer humanized doses of antifungal treatment to rats via implantable iPRECIO pumps]

https://academic.oup.com/jac/article-abstract/doi/10.1093/jac/dkaa243/5877001.

Excerpt from publication: Pumps were pre-programmed to allow repeated infusion cycles of micafungin to simulate the expected systemic exposure of a human dose of 300mg every 72h or 55mg every 24h (Tables S1 and S2, available as Supplementary data at JAC Online).

Curious to learn more? Contact Primetech and ask us about trying out our IMS-200 Application Software <click here>


Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure

Circulation Research. 2018; CIRCRESAHA. 118.312708,

https://doi.org/10.1161/CIRCRESAHA.118.312708

"The iPRECIO pump enables reliable, timed delivery of pharmacological agents. The pump was programmed for 1 hour delivery of Isoproterenol at 30ul/hr, total dose of 2mg/kg/day, once a day at the same time (1pm)"

Heart rate recordings over a period of 96 hours: showing internal consistency of iPrecio pumps Pumps inject isoproterenol once daily for a period of 1 hour. Heart rate recovers to baseline in 3-4 hours.



Figures credit Dey et al.

iPRECIO Micro Infusion Pumps for Cancer Research



More difficult to dose correctly and need more control?

Program what you require

- · Solubility issues and need a higher infusion flow-rate to reduce drug concentration and precipitation risk
- · Difficult to dose correctly and need to be able to have accurate flow-rates/dose groups
- · Suited for intermittent dosing of onco substances – daily for 1 hour or every 2 days for 2 hours.
- ·Would like to allow tumor size to grow to a certain size before drug infusion
- ·Want to program a drug holiday
- ·Want to evaluate chrono release for maximum efficacy and minimize toxicity

Cancer Research Publications

Establishment of an orthotopic bladder cancer model to evaluate continuous intravesical delivery of small molecule inhibitors in the nude rat

AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

http://cancerres.aacrjournals.org/content/75/15_Supplement/5146.short

Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept. Journal of Neuro-Oncology 2015 Oct 1.

http://link.springer.com/article/10.1007%2Fs11060-015-1947-2 http://www.ncbi.nlm.nih.gov/pubmed/26428358




Tajiri et al. (Kyushu University, Japan)

Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK 1

Cell Reports 19, 969-980, May 2, 2017

http://dx.doi.org/10.1016/j.celrep.2017.04.016
Reproduced from Tajiri et al. (CC BY-NC-ND 4.0) without modification https://creativecommons.org/licenses/by-nc-nd/4.0/



Maxim Shevtsov et al.

Granzyme B Functionalized Nanoparticles Targeting Membrane Hsp70 - Positive Tumors for Multimodal Cancer Theranostics

Small, 2019 - Wiley Online Library

https://onlinelibrary.wiley.com/doi/abs/10.1002/smll.201900205

All things mouse with iPRECIO Programmable Pumps (IMS/SMP-300 and IMS/SMP-310R)

iPRECIO Micro Infusion Pumps for Cancer Research

US20200330445A1 Continuous delivery of lenalidomide and other immunomodulatory agents [Open Access]


Marina BOROVINSKAYA, Fotios PLAKOGIANNIS, Nisarg MODI, Tamanna LATHAR, Rod L. Hartwig, James C. OLIVER

See Example 1 https://patents.google.com/patent/US20200330445A1/en?q=iprecio&q or https://lnkd.in/gerJdDA

Video (https://youtu.be/d8CHR7et5zs or https://www.linkedin.com/feed/update/urn:li:activity:6768444633161842688) from Start to 7 minutes. Rodent Studies of PK, Safety and Tolerability of LLD in Healthy and SCID Mice by Jamie Oliver Chief Medical Officer Starton Therapeutics.

Excerpts and Figure from **US20200330445A1** (SCID Mice 20 grams on average, Route of Administration (RoA) - SC)

"After the tumor reached an average size of 100-150 mm, iPrecio pump was surgically implanted into each of the mice. Dosing began twenty four hours post pump implantation. Each of Groups 3-6 was treated lenalidomide via continuous subcutaneous infusion at different hourly rate. The dosing lasted 14 days followed by one day off the treatment and lasted for another



14 days. The iPrecio pump was replaced after 14 days."

See Example 1

https://lnkd.in/gcGAg4z or https://lnkd.in/gerJdDA

"This study unexpectedly showed that the continuous infusion route effectively reduced the tumor size in all animals treated at 6 mcg/hr while the intraperitoneal injection at a higher dose slowed progression but did not inhibit the growth of the tumor size. See FIG. 1. This study also showed that the continuous infusion route did not result in substantial loss of body weight or hematologic toxicity. See FIG. 2 and Table 1." From Borovinskya et al. US 2020/0330445 A1


All things mouse with iPRECIO Programmable Pumps (IMS/SMP-300 and IMS/SMP-310R)

An adipokine feedback regulating diurnal food intake rhythms [Open Access] Tsang et al.


RESEARCH ARTICLE Jul 9, eLife 2020;9:e55388 DOI: 10.7554/eLife.55388 https://lnkd.in/gewXtMy, https://elifesciences.org/articles/55388 Excerpts and Figures 8 (A)-(C) reproduced Tsang et al. based on Attribution 4.0 International (CC BY 4.0), https://creativecommons.org/licenses/by/4.0/ No modifications made. (Adipoq-deficient mice or wild-type mice - 8 weeks of age, Route of Administration (RoA -ICV))

Figure 8 A-C Rhythmic AdipoRon administration rescues food intake rhythms and body weight in obese male mice.

(A) Treatment regimen and groups. (B–D) Daily food intake profiles (B), relative light phase food intake (C) and total daily food intake



A combination of two human monoclonal antibodies cures symptomatic rabies Open



Mouse behavioral testing. The tested animals were non - infected (n = 3 mice with iPRECIO pump + n = 4 age - related mice without iPRECIO pump), infected non - treated (n = 5), infected and treated at 7 dpi (n = 5, mice #9 to #13), and infected and treated at 8 dpi (n = 5, mice #24 to #28).


Sympathetic Overactivity in CKD Disrupts Buffering of Neurotransmission by Endothelium-Derived Hyperpolarizing Factor and Enhances Vasoconstriction. Cao et al. (CD-1 mice (6 weeks old) 20–24 g, RoA -ICV) Journal of the American Society of Nephrology. JASN July 2020, ASN.2020030234; doi. :10.1681/ASN.2020030234 https://lnkd.in/gcbu3nc

Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α7nAChR+splenocytes [Open Access]. Inoue et al. J Clin Invest. Doi: 10.1172 / JCI83658, April 18, 2016 https://www.jci.org/articles/view/83658 (Male mice, 8–12 weeks of age, 20–25 g, RoA-IV)


WO202021821A1 Pulsative gnrh administration for treating cognitive disorders [Open Access] Vincent PREVOT Andrea MESSINA Paolo GIACOBINI Valérie LEYSEN Maria MANFREDI LOZANO (Down syndrome DS - Ts65Dn mice, RoA - SC) https://patents.google.com/patent/WO2020221821A1/en?oq=WO2020221821A1

Example Pump implantation site and drug administration site

Intravenous Administration




SMP-310R




SMP-200

Intracerebral Administration



SMP-310R



Support Materials

Technical Note/Surgical Protocol:

- -Recommendation for Intravenous Administration.
- -Recommendations for Subcutaneous Administration.
- -Recommendations for Intraperitoneal Administration.
- -Recommendations for Intracerebral Administration.
- -Recommendations for Intrathecal Administration.

References

An Improved Method of Implanting a Programmable Continuous Infusion Pump in Mice. (C57BL/6 mice (44 to 52 day old , 19 to 25 g), Route of administration (RoA) - SC 68th AALAS National Meeting, October 15 to 19th 2017, Austin Convention Center, 500 E. Cesar Chavez Street, Austin, TX 78701, U.S.

Surgical Videos

Mouse Surgeries (SMP-300 / SMP-310R)



SMP-300 / SMP-310R with SC administration and general preparation video

https://drive.google.com/drive/folders/0B0pySJ1uXUqSVFBSVVAzTIZHaWc?resourcekey=0-kOMVOKHst22jjOxNE-5RyA&usp=sharing



SMP-300 / SMP-310R with IP administration

https://drive.google.com/drive/folders/080pySJ1uXUqSd1BNdDVZeEFQUWM?resourcekey=0-a8bb3m0IFMGZYvBbfFEp-w&usp=sharing



SMP-300 / SMP-310R with IV Jugular administration

https://drive.google.com/drive/folders/0B0pySJ1uXUqSbENyQ21nY2REcHM?resourcekey=0-9HPwbMFKCRttX5G7lG7dUw&usp=sharing



SMP-300 / SMP-310R with IV femoral administration

https://drive.google.com/drive/folders/0B0pySJ1uXUqSdlFtVFdJMFFncWM?resourcekey=0-GMNTGvE5ZXG9j0qS_QPNAw&usp=sharing



SMP-300 / SMP-310R with ICV administration

 $\label{lem:https://drive.google.com/drive/folders/0B0pySJ1uXUqSUGxHWkdLTXMwSEk?resourcekey=0-Uirh6Hx2Z0VIVpskbca7Tw\&usp=sharing$



Refilling Video and Refiling FAQ

https://drive.google.com/drive/folders/0B0pySJ1uXUqSX203d1l4bGsxOG8?resourcekey=0-0U5m2|7nCRxfhfJ4u3uSeA&usp=sharing

Rat Surgeries (SMP-200)



Surgery Training Videos

 $\label{lem:https://drive.google.com/drive/folders/0B0pySJ1uXUqSR2kzLVIMbWtRNUE?resourcekey=0-2iWx-iiDd7sJJPl2AZIV4A\&usp=sharing$

We have been working on surgical videos which we hope will help our users.

These are for the SMP-200 pumps you have been using

- > We have been working surgical videos unfortunately, they are not complete yet.
- > Feedback on the videos were provided by other surgeons (word document attached)
- > We have been working with Vetbiotech, www.vetbiotech.com to complete them.

Surgical Videos

From both Distributor and direct with Manufacturer (any way you want)

- · Phone
- · E-mail or fax
- Web meeting and training

iPRECIO® Key Features

- > Accurate patented Rotary Finger Method
 - Every pump is factory tested and calibrated
 - Better than ±5% accuracy
 - Programmable infusions protocols (simple and complex)
- > Totally implanted in subcutaneous space
- > Refillable (reservoir) percutaneously via refill port with re-sealable septum
- > With iPRECIO® catheters, test your drug's effects nearly anywhere
- > Easy to use software for infusion protocol programming



Implantable

The pump can be completely implanted in small laboratory animals subcutaneously. Thus, the animal moves freely without any restrain (i.e. tethering) during drug infusion. Additionally, infection risk is reduced, and the animal is likely to be significantly less stressed than in a tethered infusion model.



Refillable

You can replenish or exchange saline and/or any medical fluid in the pump via percutaneous access to the pump refill septum and reservoir after implantation of the pump. Recovery from surgery or washouts may be planned with saline in the reservoir. Long-term drug infusion can be maximized to battery life of the pump.



Precision


The technology driving the infusion is a patented "Rotary Finger" method. This method is a unique form of peristalsis. The precise "micro-stick" pushes a rubber tube in the pump in a uniform and sequential manner. The accuracy of iPRECIO is +/-5%.

Programmable


> SMP-310R 15 steps for flow rate or dose programming: 0.0-10.0 ul/hr with repeat mode


Each flow profile may contain up to 15 doses or flow rate steps. A single step would mean a fixed continuous dose or flow-rate for the study duration. A more complex infusion profile will contain more than 1 step and may contain up to 15 steps. KVO and dead volume flushing functions may be programmed within the 15 programmable steps.







> SMP-200 10 steps for flow rate programming : 0, 0.2, 0.5 & 1.0 - 30.0 ul/hr with repeat mode










iPRECIO® is an Ultimate Choice

This implantable infusion pump uses a patented, microprocessor controlled peristalsis mechanism for accurate controlled flow. It is the only implantable and programmable pump for small laboratory animals. iPRECIO® can infuse fluids continuously for as long as six months and it can be refilled via a percutaneously accessible port.




iPRECIO® Pump's Structure


> SMP-310R





> SMP-200





iPRECIO® Management System

> SMP-310R



iPRECIO® Management System is sold as IMS-310R which consists of data communication device (UCD-X10R) and Management Software, User Manual.

> SMP-200



iPRECIO® Management System consists of:

- Data Communication Device
- USB cable, 2 AAA batteries
- iPRECIO® Management Software Installation CD
- iPRECIO® User Manual

iPRECIO® Battery Life

> SMP-310R

Com.	Per minute		Every 2 hours		Every 6 hours		Every 24 hours		None	
Flow rate	Driving hours	Driving days	Driving hours	Driving days	Driving hours	Driving days	Driving hours	Driving days	Driving hours	Driving days
0.1	157	6.5	528	22.0	1063	44.3	1542	64.3	1628	67.8
0.5	155	6.5	476	19.8	887	37.0	1214	50.6	1266	52.8
1.0	153	6.4	428	17.8	742	30.9	959	40.0	991	41.3
5.0	137	5.7	263	11.0	344	14.3	357	14.9	362	15.1
8.0	127	5.3	207	8.6	243	10.1	243	10.1	245	10.2
10.0	121	5.0	178	7.4	196	8.2	200	8.3	201	8.4

Flow Rate Unit: µL/hr

> SMP-200

Flow Rate	Infus	Total Volume				
Flow Rate	Time (h)	Days (approx.)	Total volume			
30.0 µL/hr	196 hr	1 week	5.8 ml			
19.0 μL/hr	307 hr	1.8 weeks	5.8 ml			
8.5 µL/hr	669 hr	1 month	5.6 ml			
1.0 uL/hr	4.328 hr	6 months	4.3 ml			

^{*} Table above outlines the maximum battery life for the programmed protocol and pump switch on time.

Exact battery life will be dependent on pump switch on time, programmed infusion protocol, and selected communication availability(Com.). iPRECIO Management software helps the user calculate battery life for selected programming.

Model	SMP-310R IMS-310R (new!!)	SMP-300 IMS-300 (discontinued)	SMP-200 IMS-200		
Appearance of the pump	24.8(L) x 15.0(W) x 7.2 (H)	24.8(L) x 15.0(W) x 7.2 (H)	38.7 (L) X 19.2 (W) X 9.7 (H)		
	mm, Max. height 7.5mm	mm, Max. height 7.4mm	mm		
Туре	Implantable SC	Implantable SC	Implantable SC		
Volume / Weight	2.26cc / 3.4g	2.15cc / 3.3g	7.20cc / 7.9g		
Animal Species	Mouse or larger	Mouse or larger	Rats or larger		
Reservoir Volume	130 µL	130 µL	900 μL		
Flow Rate (Setting Resolution)	0.0 – 10.0 μL/hr (0.1μL/hr)	0.0 – 10.0 μL/hr (0.1μL/hr)	0.0, 0.2, 0.5&1.0 – 30.0µL/hr (0.1µL/hr)		
Flow Steps / Repeat	15 / Yes	15 / Yes	10 / Yes		
	0 & 0.1 ul/hour 67 days	0 & 0.1 ul/hour 46 days	0, 0.2, 0.5, 1 µl/hour - 6 mths		
Battery Life	1 µl/hour up to 41 days	1 μl/hour up to 33 days	2.5 µl/hour - 86 days		
	10 μl/hour up to 8 days	10 μl/hour up to 9 days	30 μl/hour - 8 days		
Programmable	Wireless Preprogrammable	Wireless Preprogrammable	Preprogrammed prior to implantation		
Wireless Distance	1 – 6m	< 1m	-		
Communication Availability	1m, 1h, 2h, 4h, 6h, 12h, 24h and NONE (8 choices)	1m, 2h, 6h, 24h and None (4 choices)	-		

Compatible solvents for SMP-300, 310R and SMP-200

* Tested for both SMP-200 & SMP-300 / SMP-310R

* Tested in SMP-200 Pump Only

(same materials and manufacturing process) and expected to be compatible when compatible. Also, not compatible when not compatible.

Compatible Solvents

Acids, with pH 2 or weaker *

Bases, with pH less than 13

Buffered Phosphate Saline (PBS) *

Culture Media (1% benzyl alcohol) *

Cyclodextrin *

Dextrose, up to 5% in water or saline *

N,N-Dimethyl formamide (DMF), up to 25% in water *

DMSO 50% and water or saline 50%

DMSO, up to 50% in ethanol (≤15%) and water *

DMSO 5% and PEG400 95%

50% DMSO + 50% Propylene Glycol *

DMSO 50% and water 50%

DMSO 50% + 15% ethanol and 35% water *

Dulbecco's Modified Eagle Medium (D-MEM) (1X), liquid *

Ethanol, up to 50% in water

Glycerin, up to 75% in water *

Glycerol 100%

1-Methyl-2-Pyrrolidone, up to 12.5% in water *

Propylene Glycol *

Ringer's solution (without lactate) *

Saline, 0.9% (or other aqueous salt solution) *

Triacetin, up to 5% in water *

Tween 80, up to 2% in water *

Water, distilled *

PEG200 100% *

Solutol® 15% in water *

Viscosity up to 20 cp is ok.

(Higher viscosity not tested due to the use of 27G needles.

Difficulty to aspirate solution with 27G needle)

Short term use only (1 - 2month)

PEG300 100% * (< 45 days)

PEG400 100%

Cremophor EL 25% in water * (< 30 days)

PEG400/Propylene Glycol/Water 30:50:20*(<30 days)

Rev19 Jul.2022

